Lauren Hartle
Analista de Capital Privado en Prime Impact Fund .
Perfil
Lauren Hartle is currently an Associate at Prime Impact Fund since 2020.
Previously, she worked as a Development Technician at AlphaVax, Inc. from 2008 to 2009.
Dr. Hartle holds a doctorate degree from Harvard University and an undergraduate degree from the University of North Carolina System, which she received in 2007.
Cargos activos de Lauren Hartle
Empresas | Cargo | Inicio |
---|---|---|
Prime Impact Fund
Prime Impact Fund Investment ManagersFinance Prime Impact Fund (Prime Impact) is a venture capital firm founded in 2018 by Johanna Wolfson and Matthew Nordan. The firm is headquartered in Cambridge, Massachusetts. | Analista de Capital Privado | 01/06/2020 |
Antiguos cargos conocidos de Lauren Hartle.
Empresas | Cargo | Fin |
---|---|---|
AlphaVax, Inc.
AlphaVax, Inc. Pharmaceuticals: MajorHealth Technology AlphaVax, Inc. involves in clinical-stage biopharmaceutical company. It develops vaccine technology bio products. The firm products include Alphavax and pipleline bio products. It focuses on commercial potential of its alphavaccine vector technology in cancer immunotherapy. The company was founded in 1997 and is headquartered in Durham, NC. | Corporate Officer/Principal | 01/06/2009 |
Formación de Lauren Hartle.
Harvard University | Doctorate Degree |
University of North Carolina System | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Prime Impact Fund
Prime Impact Fund Investment ManagersFinance Prime Impact Fund (Prime Impact) is a venture capital firm founded in 2018 by Johanna Wolfson and Matthew Nordan. The firm is headquartered in Cambridge, Massachusetts. | Finance |
AlphaVax, Inc.
AlphaVax, Inc. Pharmaceuticals: MajorHealth Technology AlphaVax, Inc. involves in clinical-stage biopharmaceutical company. It develops vaccine technology bio products. The firm products include Alphavax and pipleline bio products. It focuses on commercial potential of its alphavaccine vector technology in cancer immunotherapy. The company was founded in 1997 and is headquartered in Durham, NC. | Health Technology |
- Bolsa de valores
- Insiders
- Lauren Hartle